
Attending Nephrologist @NefrologiaINC | Cardiorenal @geshNHS | Critical Care Nephrology @UAB_NRTC | POCUS | Music Lover | Calisthenics
Muddy Banks Of The Wishkah
Joined December 2009
- Tweets5.6K
- Following441
- Followers829
- Likes8.1K
Pinned Tweet
Un día en la mejor unidad de HDF del país
Decidí explicar cómo es un día en la vida del residente de nefrología en la que yo (y muchos) consideran la mejor unidad de HDF.
🧵 🚨 🧵
VictorHugoG.Johnson retweeted
CRRT loses ~0.2 g of amino acids/L of effluent, or 10-15 g/day. IRRT loses ~12 g/session, and 5-10 g/day of protein may be lost. Water-soluble vitamins, selenium + copper are also at risk. 🎩 tip to the authors, including @SLCutuli @MarliesOst @emjsee
eddyjoemd.com/foamed
VictorHugoG.Johnson retweeted
IV iron in #HFpEF : The #IRONMET-HFpEF Randomized Trial
📍 65 patients randomized to ferric derisomaltose 1000 mg IV vs placebo; 98.5% completed 12-week follow-up.
📍 Peak VO₂ improved significantly: +1.2 vs +0.1 mL/kg/min; LS mean difference +1.1 mL/kg/min (95% CI 0.2–1.9), P=0.02
📍 Functional gains: anaerobic-threshold VO₂, 6-minute walk distance, and NYHA class all improved vs placebo; KCCQ-OSS was not significantly different.
📌 Iron stores were effectively repleted with higher TSAT and ferritin, with no serious adverse events attributed to ferric derisomaltose
ahajournals.org/doi/10.1161/…
@AHAScience #ScientificSessions26 #AHA26
#HFpEF #HeartFailure #IronDeficiency @CircAHA
VictorHugoG.Johnson retweeted
Spironolactone is the workhorse diuretic for ascites.
But it has side effects. Below I address the conversion to eplerenone. Now let’s try another:
let’s say someone has uncontrolled ascites on 100mg of spiro. What dose and frequency of AMILORIDE would you use?
Replying to @ebtapper
1️⃣Eplerenone is weaker than spiro by ~50% (pmid 2949071).
2️⃣the doses used in CHF🫀 are low! and Epic will warn you that high doses are unsafe (unlike spiro). Scary!
3️⃣best to switch 1:1 or be prepared to rapidly increase
4️⃣eplero half life is 4-6 hours, BID may be necessary!
VictorHugoG.Johnson retweeted
🔴🔴Lp(a)HORIZON (@NEJM): pelacarsén 80 mg/mes bajó la Lp(a) de 236 a 64 nmol/L… y NO redujo eventos.
MACE-4: 12,3 % vs 12,1 %; HR 1,02 (0,90–1,15) a 4,7 años.
n = 8322 con ECV y Lp(a) ≥70 mg/dL.
Bajar la Lp(a) no es lo mismo que bajar eventos. 🧵
VictorHugoG.Johnson retweeted
🫀Pharmacological treatment strategies to prevent #heartfailure across the cardiovascular-kidney-metabolic spectrum, an EJHF expert consensus statement:
📍Identify individuals at risk of developing HF:
- Type 2 diabetes
- Chronic kidney disease ± albuminuria
- Hypertension and obesity
- Atherosclerotic cardiovascular disease
- Metabolic dysfunction-associated steatotic liver disease
📍Four foundational pharmacological strategies:
💊RAS inhibitors (ACEi/ARBs)
💊SGLT2 inhibitors
💊Non-steroidal MRAs (finerenone)
💊Incretin-based therapies (GLP-1 RAs and dual GLP-1/GIP agonists)
📍Early, accelerated treatment implementation:
- Initiate complementary therapies early rather than delaying until clinical deterioration
- Titrate rapidly and avoid unnecessary discontinuation
- Individualize treatment according to clinical phenotype, risk, and tolerability
📍Structured monitoring and multidisciplinary care:
- Laboratory monitoring at 1-4 weeks
- Reintroduce therapies following temporary interruption when appropriate
- Support nurse/pharmacist-led titration, digital monitoring, and patient education
📍Overcome implementation barriers:
- Clinical inertia and polypharmacy
- Renal safety concerns
- Treatment costs and inequities
- Fragmented healthcare delivery
Read more in #EJHF @EJHFEiC : doi.org/10.1093/ejhf/xuag301
@escardio #HFA_ESC #HF #CKM
VictorHugoG.Johnson retweeted
IHD vs CRRT again. ICRAKI was stopped early due to higher mortality with IHD. Real signal or truncation artifact? And was IHD given the way we'd give it to a patient on vasopressors? #NephJC #nephtwitter
✍️ By @rn_flex @DivyaveerSSNeph
nephjc.com/news/icraki11126
VictorHugoG.Johnson retweeted
Let's gossip about contractility!!
Contractility is not stroke volume!
#icu #criticalcare #cardiology #pedsicu #pedscards #medicine #foamed #medtwitter #cicu #micu #picu #nicu #echofirst
@OungSavly @WithAScalpel @alex1708ander
VictorHugoG.Johnson retweeted
El deterioro de función renal observado al descongestionar con diuréticos no sería debido a la depleción de volumen, se explica mejor por los mecanismos intrarrenales que se originan. Aquí la compleja explicación
Hypertension 2026
10.1161/HYPERTENSIONAHA.126.27712
VictorHugoG.Johnson retweeted
Our research letter published in @EJIM_journal explores urinary calcium excretion as a potential biomarker of diuretic resistance in heart failure, presenting a hypothesis-generating study. ejinme.com/article/S0953-620…
VictorHugoG.Johnson retweeted
Los invitamos a participar en el 1er encuentro Cardiorrenal Iberoamericano con colaboración @SLANH_ @SENefrologia @IMINmx., en el marco de la #semanaIMIN. Tendremos contenido académico de gran nivel con profesores de LATAM y España. No se lo pierdan! @SLANHJoven @visanpolo
VictorHugoG.Johnson retweeted
🫀Finerenone vs spironolactone in heart failure with mildly reduced or preserved ejection fraction: a real-world study. see@ ow.ly/LcYk5100u04
@EJHFEiC @AmrAbdin10 @GiuseppeGalati_ @HanCardiomd @EJHFEiC @JanBiegus @ppponikowski #HFA_ESC @hvanspall @FudimMarat @gcfmd @MarcoMetra @GianluSava
#ESCHeartFailure
VictorHugoG.Johnson retweeted
GDMT is Associated with Reduced Loop Diuretic Requirements, Whereas Diuretic Dose Does Not Modify GDMT Benefit in Heart Failure: STRONG-HF.
GDMT optimization acted as diuretic-sparing therapy: reaching target doses, particularly of all three classes, was associated with markedly lower LD requirement.
@hfcollaboratory @gcfmd @SJGreene_md @mvaduganathan
academic.oup.com/eurjhf/adva…
VictorHugoG.Johnson retweeted
Management of Heart Failure With Preserved Ejection Fraction: 2026 ACC Expert Consensus Decision Pathway: A Report of the American College of Cardiology Solution Set Oversight Committee
HFpEF: beyond EF!
ACC 2026:
• SGLT2i ± finerenone if eligible
• Incretins for obesity
• Diuretics for congestion
• ARNI by phenotype
• No routine beta-blockers without a specific indication
Tailor care to phenotype and sex.
#HFpEF #CardioTwitter
@mvaduganathan @gcfmd @SJGreene_md @JavedButler1 @BiykemB
jacc.org/doi/10.1016/j.jacc.…
VictorHugoG.Johnson retweeted
Early Discharge Strategy Including Subcutaneous Furosemide in Hospitalized Heart Failure | JACC jacc.org/doi/full/10.1016/j.… @msanchezmar @mrcsgmb84 @iria_ro @chemachir @IcyfaSemi @rdelaespriella @paullaceriborra @jc_trullas @MartaCoboMarcos @BeatrizSeoane79 @JesusCasado20
VictorHugoG.Johnson retweeted
📢 1-Y outcomes in 🇪🇸CardioRen
🔹 Kidney Function was associated with ⬆️events
🔹 Event rates were ⬇️than historical cohorts.
🔹 eGFR predicted mortality, but not the composite outcome.
🔹 Congestion and comorbidities ➡️key drivers of morbidity.
revespcardiol.org/en-prognos…
VictorHugoG.Johnson retweeted
Monitoring and dose adjustment of regional citrate anticoagulation for continuous renal replacement therapy
CCR Journal Watch
criticalcarereviews.com/late…
VictorHugoG.Johnson retweeted
Following a recommendation from the DMD Boehringer Ingelheim has decided to discontinue the EASi-KIDNEY trial (NCT06531824)
Testing vicadrostat (BI 690517), in combination with empagliflozin vs empagliflozin alone, could slow CKD and ⬇️ CV events
boehringer-ingelheim.com/hum…
VictorHugoG.Johnson retweeted
Simplemente no hay evidencia para prescribir espironolactona en personas en diálisis, aquí los ensayos clínicos que no demostraron beneficio:
•SPin-D❌
•MiREnDa❌
Y con más detalle👇🏻
•ALCHEMIST ❌
•ACHIEVE ❌
AJKD 2026
10.1053/j.ajkd.2026.04.020
VictorHugoG.Johnson retweeted
‘26 HF RCTs
HFpEF
GLP1: #MARITIME #HFPolaris #ELEVATE
sMRA: #SPIRRIT
nsMRA: #REDEFINE
ASi: #EASiHFPres
CMI: #AURORA #AMBER #EQUINOX
HFrEF
GLP1: #Enith
nsMRA: #FINALITY
ASi: #EASiHFRed
Myosin Act: #COMET
Colchicine: #COLHEF
IV Fe: #ICONIC
All LVEF
nsMRA: #BalanceD #CONFIRMATION










































